• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Gynecological endocrinology: the official journal of the International Society of Gynecological Endocrinology >GnRH antagonist versus follicular-phase single-dose GnRH agonist protocol in patients of normal ovarian responses during controlled ovarian stimulation
【24h】

GnRH antagonist versus follicular-phase single-dose GnRH agonist protocol in patients of normal ovarian responses during controlled ovarian stimulation

机译：GNRH拮抗剂对卵巢刺激正常卵巢反应患者的卵泡拮抗剂与卵泡相单剂量GNRH激动剂协同

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: This study aims to explore the differences of the ovarian stimulation (OS) characteristics, laboratory, and clinical outcomes between follicular-phase single-dose gonadotropin-releasing hormone (GnRH) agonist protocol and GnRH antagonist protocol during controlled ovarian hyperstimulation (COH). Methods: About 1883 consecutive IVF/ICSI fresh cycles of normal ovarian responders were retrospectively analyzed, with 1229 in the single-dose GnRH agonist protocol group and 654 in the GnRH antagonist protocol group at Reproductive Medical Center of Tongji Hospital from 1 January 2014 to 31 December 2017. Results: The follicular-phase single-dose GnRH agonist group showed significantly more oocytes obtained, higher implantation rate and pregnancy rate, as well as lower luteinizing hormone (LH) level and estradiol (E2)/oocyte ratio on the day of human chorionic gonadotropin (hCG) administration. However, differences were not significant in meiosis II (Mil) oocyte rate, two pronuclear zygote (2PN) embryo rate, viable embryo rate or high-quality embryo rate, compared with the GnRH antagonist group. Further comparison of clinical outcomes in the first frozen-thawed cycles did not show significant difference in either implantation or clinical pregnancy rate between the two protocol groups. Conclusions: Follicular-phase single-dose GnRH agonist protocol may achieve better clinical outcomes in normal ovarian responders, which could be explained more by positive effect on endometrial receptivity rather than embryo quality.
机译：目的：本研究旨在探讨卵巢刺激（OS）特征，实验室和临床结果在受控卵巢过度刺激期间（COH）期间卵泡相单剂量促性腺激素释放激素（GNRH）激动剂方案和GNRH拮抗剂方案之间的卵巢刺激（OS）特征，实验室和临床结果的差异。方法：回顾性分析了大约1883年的正常卵巢响应者的新鲜循环，在2014年1月1日至31日，单剂量GNRH激动率协议组和654年在通知医院的生殖医疗中心的GNRH拮抗剂议定书组中。结果：结果：卵泡相单剂量GNRH激动剂组显示出更多的卵母细胞，植入率高，妊娠率较高，以及较低的叶黄素激素（LH）水平和雌二醇（E2）/卵母细胞比例人绒毛膜促性腺激素（HCG）给药。然而，与GNRH拮抗剂组相比，分裂II（MIL）卵母细胞率，两种强核卵细胞率，可行的胚胎率或高质量胚胎速率的差异不显着。进一步比较第一冷冻循环中的临床结果的比较在两种方案组之间的植入或临床妊娠率的临床患病中没有显着差异。结论：卵泡相单剂量GnRH激动剂方案可以在正常卵巢响应者中达到更好的临床结果，这可以通过对子宫内膜接受性而不是胚胎质量进行更多的解释。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号